Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Manufacturing Process Comparison in HNC
NCT01081041Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2010
- Primary completion
- Aug 2013
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of KL-140 in head and neck squamous cell carcinoma (HNSCC), sponsored by Eli Lilly and Company. Started Jun 2010; status: completed.
02
Drugs
KL-140
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01081041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01081041.